• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Jade Biosciences Inc.

    5/5/25 4:26:12 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JBIO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    JADE BIOSCIENCES, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    008064206

    (CUSIP Number)


    04/28/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    008064206


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,220,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,220,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,220,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    008064206


    1Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,220,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,220,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,220,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    008064206


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,220,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,220,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,220,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    008064206


    1Names of Reporting Persons

    VHCP Management III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,220,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,220,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,220,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    008064206


    1Names of Reporting Persons

    VHCP Management EG, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,220,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,220,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,220,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    008064206


    1Names of Reporting Persons

    Nimish Shah
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,220,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,220,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,220,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    008064206


    1Names of Reporting Persons

    Bong Y Koh
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,220,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,220,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,220,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    JADE BIOSCIENCES, INC.
    (b)Address of issuer's principal executive offices:

    930 WINTER STREET, SUITE M-500, WALTHAM, MA, 02451.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
    (c)Citizenship:

    All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    008064206
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 570,656 shares of common stock and pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 432,415 shares of common stock held by VHCP III, (ii) 57,017 shares of common stock and Pre-Funded Warrants exercisable for up to 43,204 shares of common stock held by VHCP Co-Investment III, and (iii) 2,592,691 shares of common stock and Pre-Funded Warrants exercisable for up to 1,964,611 shares of common stock held by VHCP EG. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, VHCP III, VHCP Co-Investment III and VHCP EG, together with their affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding of the Issuer. VHCP III, VHCP Co-Investment III and VHCP EG are currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 3,220,369 shares of common stock. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
    (b)Percent of class:

    Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage is 9.99%. Such percentage is based upon the sum of (i) 32,235,926 shares of common stock outstanding as of April 28, 2025, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on May 1, 2025 and (ii) 5 shares of common stock issuable upon the exercise of the Pre-Funded Warrants. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Venrock Healthcare Capital Partners III, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:05/05/2025
     
    VHCP Co-Investment Holdings III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
    Date:05/05/2025
     
    Venrock Healthcare Capital Partners EG, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:05/05/2025
     
    VHCP Management III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:05/05/2025
     
    VHCP Management EG, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:05/05/2025
     
    Nimish Shah
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:05/05/2025
     
    Bong Y Koh
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:05/05/2025
    Exhibit Information

    Exhibit 24.1 Power of Attorney for Bong Koh Exhibit 24.2 Power of Attorney for Nimish Shah Exhibit 99.1 Joint Filing Agreement

    Get the next $JBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JBIO

    DatePrice TargetRatingAnalyst
    5/7/2025$17.00Outperform
    Wedbush
    5/5/2025$19.00Buy
    Stifel
    5/2/2025$10.00Buy
    TD Cowen
    More analyst ratings

    $JBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Jade Biosciences with a new price target

      Wedbush initiated coverage of Jade Biosciences with a rating of Outperform and set a new price target of $17.00

      5/7/25 8:42:40 AM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Jade Biosciences with a new price target

      Stifel initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $19.00

      5/5/25 8:31:27 AM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Jade Biosciences with a new price target

      TD Cowen initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $10.00

      5/2/25 8:14:47 AM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JBIO
    Financials

    Live finance-specific insights

    See more
    • Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

      SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered

      6/2/25 7:00:00 AM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JBIO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Jade Biosciences Inc.

      SCHEDULE 13G - Jade Biosciences, Inc. (0001798749) (Subject)

      6/6/25 10:03:48 AM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jade Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - Jade Biosciences, Inc. (0001798749) (Filer)

      5/14/25 4:12:22 PM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Jade Biosciences Inc.

      SCHEDULE 13G - Jade Biosciences, Inc. (0001798749) (Subject)

      5/5/25 4:26:12 PM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

      SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered

      6/2/25 7:00:00 AM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the quarter ending March 31, 2025, and provided a corporate update. "The start to 2025 marked a defining period for Jade Biosciences

      5/14/25 4:05:00 PM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

      SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York.   Tom Frohlich, Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m. ET. Members of the management team will also host investor meetings during the conference. Investors and the general public are invited to listen to the session by visiting the Investors and Media page on JadeBiosciences.com. An archived e

      5/13/25 7:00:00 AM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Frohlich Tom bought $44,400 worth of shares (6,000 units at $7.40) (SEC Form 4)

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/19/25 4:54:17 PM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Frohlich Tom bought $44,400 worth of shares (6,000 units at $7.40) (SEC Form 4)

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/19/25 4:54:17 PM ET
      $JBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care